In Corporate News, Press Releases, Science News

VERO BEACH, FL / ACCESSWIRE / September 13, 2022 / Nascent Biotech, Inc. (OTCQB:NBIO) (“Nascent Biotech”, “Nascent”, or the “Company”), a clinical-stage biotechnology Company pioneering the development of monoclonal antibodies targeting various cancer types, announced today the completion of the Fourth Cohort in dosing patients in the Company’s Phase I trial to evaluate Pritumumab (“PTB”) as a treatment for Brain Cancer, including Primary and metastatic Brain Tumors.

After reviewing data gathered from the four completed cohorts, this milestone will allow the trial to advance to a fifth and final cohort. Patient enrollment continues for Phase I and interested parties may review trial requirements at under the search term ‘Pritumumab’.

Following completion of dosing of the Fifth Cohort, the Phase I trial will be complete, and the Company will prepare data for submission to the FDA in preparation for Phase 2 clinical research.

“Having completed four cohorts, we are enthusiastic about moving to our fifth and likely final cohort in the Phase I trial,” noted Nascent CEO, Sean Carrick. “The data received so far has been very encouraging. We will continue to perform PK studies on the fourth and fifth cohorts to support an upcoming data submission to the FDA.”

PTB is a natural human antibody that binds to Cell surface Vimentin (also referred to as ectodomain vimentin), a protein expressed on the surface of epithelial cancers. PTB is used as a targeted immunotherapy and seek out only cancer cells without damaging healthy cells.

About Nascent Biotech
Nascent Biotech, Inc. (OTCQB:NBIO) is a clinical-stage biotech company pioneering the development of monoclonal antibodies to be used in the treatment of various cancers and viral infections, helping people worldwide. Its products are not yet commercially available. The Company’s lead candidate, Pritumumab (PTB), is a monoclonal Antibody (Mab) that is being studied in Phase I clinical trials for the treatment of Brain Cancer.

For further information please visit our website

Forward-Looking Safe Harbor Statement
Statements in this press release about our future expectations constitute ‘forward-looking statements’ within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and as that term is defined in the Private Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties and are subject to change at any time and our actual results could differ materially from expected results. These risks and uncertainties include, without limitation, Nascent Biotech Inc’s ability to target the medical professionals; Nascent Biotech Inc’s ability to raise capital; as well as other risks. Additional information about these and other factors may be described in the Nascent Biotech Inc’s Form 10, filed on May 2, 2015, and future subsequent filings with the Securities and Exchange Commission. The Company undertakes no obligation to update or release any revisions to these forward-looking statements to reflect events or circumstances after the date of this statement or to reflect the occurrence of unanticipated events, except as required by law.

Corporate Contact
Sean Carrick | President | CEO | Nascent Biotech, Inc.
772.713.0541 Cell |

Public Relations
EDM Media, LLC
(800) 301-7883

Recent Posts
Nascent Biotech logoNascent Biotech logo